Monitor future filings for potential milestone payments or revenue recognition from this collaboration. The lack of disclosed financial terms limits near-term revenue impact, but the partnership with a major pharma validates Alamar's technology platform.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alamar Biosciences announced a strategic scientific collaboration with GSK to use its NULISA platform for large-scale proteomic profiling of over 60,000 serum samples across multiple disease areas. The deal provides validation for Alamar's technology but does not disclose financial terms, limiting immediate revenue visibility.
Key Facts
- Collaboration with GSK to analyze >60,000 serum samples using Alamar's NULISAseq panels
- Focus areas include proteomic correlates of disease outcomes, biomarker identification, mechanistic endotyping, and drug response
- No financial terms (upfront, milestones, or royalties) disclosed in the press release
- Alamar reported Q3 2026 revenue of $33.5M (+68% YoY) and raised full-year guidance to $121M-$123M in a separate 8-K filed the same day
- Net loss widened to $13.3M from $8.0M in Q3 2025
Financial Impact
No financial terms disclosed; collaboration provides platform validation but no immediate revenue contribution
Risk Factors
- No financial terms disclosed, making revenue contribution uncertain
- Collaboration is exploratory; may not lead to commercial products or sustained revenue
- Net loss widening indicates rising operating expenses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | Press Release | $27.39 | awaiting T+60 | awaiting T+60 | $27.39 (−0.00%) |
Nov 3, 2026 1d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Nov 3, 2026 1d ago | Press Release | $31.50 | awaiting T+60 | awaiting T+60 | $27.39 (−13.05%) |
Nov 3, 2026 1d ago | Press Release | $31.50 | awaiting T+60 | awaiting T+60 | $27.39 (−13.05%) |
Nov 2, 2026 1d ago | Press Release | $30.22 | awaiting T+60 | awaiting T+60 | $27.39 (−9.36%) |
Oct 14, 2026 20d ago | 144 | $27.42 | awaiting T+60 | awaiting T+60 | $27.39 (+0.11%) |
Oct 14, 2026 20d ago | 144 | $27.42 | awaiting T+60 | awaiting T+60 | $27.39 (+0.11%) |
Oct 14, 2026 20d ago | 144 | $27.42 | awaiting T+60 | awaiting T+60 | $27.39 (−0.11%) |
Oct 5, 2026 4w ago | Press Release | $32.26 | awaiting T+60 | awaiting T+60 | $27.39 (−15.10%) |
Sep 24, 2026 5w ago | Press Release | $32.80 | awaiting T+60 | awaiting T+60 | $27.39 (−16.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers